Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
Surmodics, Inc. (SRDX)
Last surmodics, inc. earnings: 4/29 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
surmodics.gcs-web.com/investor-overview
Company Research
Source: Business Wire
PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Updated safety and performance data from 160 patients with symptomatic infrainguinal vessels will be shared. EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Sean Lyden, Dr. Joseph Campbell, and Dr. Peter Monteleone, will present and discuss updated safety and performance data from the PROWL registry on 160 patients with symptomatic lower extremity (infrainguinal) vessels treated with the Pounce™ Thrombectomy Platform. The presentation will be held on Monday, November 3rd in an industry-sponsored session at the 23rd Annual VIVA Conference in Las Vegas, Nevada.TITLE: Real-world Clinical Outcomes and Case Insights of the Novel Pounce™ Thrombectomy Platform: Non-Aspiration Mechanical Treatme
Show less
Read more
Impact Snapshot
Event Time:
SRDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRDX alerts
High impacting Surmodics, Inc. news events
Weekly update
A roundup of the hottest topics
SRDX
News
- Surmodics gains as FTC won't appeal denial of GTCR deal injunction [Seeking Alpha]Seeking Alpha
- Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today [Yahoo! Finance]Yahoo! Finance
- Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire TodayBusiness Wire
- Surmodics (NASDAQ:SRDX) was downgraded by analysts at Barrington Research from a "market perform" rating to an "underperform" rating.MarketBeat
- Judge denies FTC's bid to block $627M Surmodics buyout [Yahoo! Finance]Yahoo! Finance
SRDX
Earnings
- 8/8/25 - Beat
SRDX
Sec Filings
- 11/20/25 - Form SCHEDULE
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- SRDX's page on the SEC website